EURO DIFFUSION MEDICALE

Euro Diffusion Médicale specialises in manufacturing ultrasound coupling gels. These products are formulated for use in medical imaging, specifically echoography (ultrasound), and come in various forms such as single-use flacons (e.g., 250ml) and bulk containers (e.g., 5L). Examples include standard echoography gels, premium-grade variants, and specialised formulations like Sonecho and Polaris (including blue-tinted versions). These gels are designed to enhance ultrasound imaging across specialties such as cardiology, gynaecology, radiology, and sports medicine.

Euro Diffusion Médicale is based in France. Its devices fall under the EU medical device regulations, specifically classified as Class I. Class I devices typically require conformity assessment procedures such as self-certification by the manufacturer or involvement of a notified body, depending on the risk profile. Since these are low-risk products (e.g., ultrasound gels), the regulatory pathway is streamlined but still governed by EU standards to ensure safety and performance.

Yes, Euro Diffusion Médicale’s devices are listed in EUDAMED, the European Union’s medical device registry. EUDAMED serves as a transparent database for tracking authorised medical devices across the EU, including their classification, manufacturer details, and regulatory status. Since these products are Class I, they must be registered in EUDAMED to comply with EU medical device legislation, ensuring traceability and accountability for compliance with EU requirements.

Euro Diffusion Médicale’s ultrasound coupling gels are classified as Class I medical devices under EU regulations. This classification is determined by their intended use—facilitating ultrasound imaging—and their low-risk profile, as they do not actively influence treatment or pose significant health risks. Class I devices are generally considered safe for their intended purpose when used as directed, which is why they undergo simplified conformity assessment procedures (e.g., self-certification) rather than rigorous pre-market approval.